Bruker

BRKR

Market cap $5.93B

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and da.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue to shrink and systems become increasingly more complex. As the largest supplier of nanoscale infrared (nanoIR) spectroscopy technology to the semiconductor industry, Bruker is expanding the use of AFM-IR beyond its established role in nano.

BRKR faces macro and currency headwinds, but strong BSI Nano growth, AI-driven demand and BioSpin innovations support its long-term outlook.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: “Bruker is delighted that Thierry is joining our Board. I have admired his su.

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical.

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet.

ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker's category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,.

ST. LOUIS--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants. New releases in Bruker ProteoScape™, OmniScape™, and GlycoScape™ software now support database-independent PTM discovery, confident proteoform characterizatio.

Examine the evolution of Bruker's (BRKR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

BRKR's Q4 EPS miss estimates as margins plunge and shares fall 2.7% despite a revenue beat, while the 2026 outlook targets 4%-5% sales growth.